Core Insights - AC Immune SA announced positive interim results from the Phase 2 VacSYn trial for ACI-7104.056, an active immunotherapy targeting alpha-synuclein in early Parkinson's disease, indicating potential to slow disease progression [2][4][11] Interim Results - The VacSYn trial is a placebo-controlled, biomarker-based Phase 2 study involving 34 patients, with all participants treated for at least 12 months [5] - Interim results demonstrated that all target criteria for immunogenicity were met, with a 100% responder rate and a clear safety profile [6][10] - Antibody titers in serum were over 500-fold higher in the treatment group compared to placebo, indicating a robust immune response [7][8] Biomarker and Clinical Assessments - Disease-related biomarkers showed stabilization in the treatment group, including total CSF alpha-synuclein levels and neurofilament light chain (NfL) [12] - Clinical measures indicated a trend for stabilization of motor symptoms in the active treatment group, with no meaningful progression in MDS-UPDRS Part III scores [9][12] Expert Commentary - Dr. Andrea Pfeifer, CEO of AC Immune, emphasized the potential of ACI-7104.056 to transform Parkinson's disease treatment based on the interim data [4] - Dr. Werner Poewe highlighted the promising consistency of trends across multiple biomarkers and clinical assessments, suggesting beneficial effects on disease progression [4] Future Development Plans - Based on the interim results, AC Immune plans to seek regulatory feedback to accelerate the clinical development plan towards registration [11] - Final data from Part 1 of the VacSYn trial is expected in mid-2026 [11]

Core Insights - AC Immune SA announced positive interim results from the Phase 2 VacSYn trial for ACI-7104.056, an active immunotherapy targeting alpha-synuclein in early Parkinson's disease, indicating potential to slow disease progression [2][4][11] Interim Results - The VacSYn trial is a placebo-controlled, biomarker-based study involving 34 patients, with participants treated for at least 12 months [5] - Interim results demonstrated that all target criteria for immunogenicity were met, with a 100% responder rate for antibody production [6] - ACI-7104.056 showed a clear safety profile with no clinically relevant safety issues reported, and the most common adverse events were transient injection site reactions (56%), headaches (15%), and fatigue (12%) [10] Biomarker and Clinical Assessments - Disease-related biomarkers indicated stabilization of Parkinson's disease pathology, with total CSF alpha-synuclein levels stabilizing in the treatment group while decreasing in the placebo group [13] - Neurofilament light chain (NfL) levels remained stable in the treatment group, suggesting a potential slowing of neuronal damage, while increasing in the placebo group [13] - Clinical measures, including the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III scores, showed no meaningful progression in the treatment group compared to an expected increase in the placebo group [13] Expert Commentary - Dr. Andrea Pfeifer, CEO of AC Immune, emphasized the potential of ACI-7104.056 to transform Parkinson's disease treatment and indicated plans to discuss regulatory pathways for clinical development [4] - Dr. Werner Poewe highlighted the promising consistency of trends across multiple biomarkers and clinical assessments, supporting further development of the program [4] Future Plans - Based on the interim results, AC Immune aims to seek regulatory feedback to potentially accelerate the clinical development plan for ACI-7104.056 towards registration, with final data from Part 1 of the trial expected in mid-2026 [11]

Summary of AC Immune Conference Call Company Overview - **Company**: AC Immune (NasdaqGM: ACIU) - **Focus**: Development of precision medicine for neurodegenerative diseases, particularly through active immunotherapy and small molecules [3][4] Key Points Pipeline and Financials - AC Immune has a focused pipeline with several phase two products and wholly owned assets [3] - The company has generated over $430 million from partnerships, with potential for an additional $4 billion in milestones and royalties [3] - Cash reserves are projected to last until Q3 2027, allowing for investment in precision medicine [3] Active Immunotherapy Programs - Lead programs ACI-35.030 and ACI-24 are partnered with Johnson & Johnson and Takeda, both receiving fast-track designation from the FDA [4] - ACI-7104, an active immunotherapy against alpha-synuclein, is in phase two development, with data expected by the end of the year [4][15] Precision Medicine Approach - The company emphasizes the importance of precision medicine in neurodegenerative diseases, particularly in Alzheimer’s, where there are approximately 100 million patients and 300 million at risk [5] - Active immunotherapies and small molecules target various proteins involved in neurodegenerative diseases, including tau and alpha-synuclein [6] Small Molecule Development - Small molecules derived from the Morphomer platform can penetrate the brain and target misfolded proteins, showing potential for preventing neurotoxicity [6][7] - The Tau morphomer (664) demonstrated over 50% reduction in Tau pathology in aggressive mouse models [9] - NLRP3 inhibitors are in development for CNS applications and show promise in treating diseases like Parkinson's and Alzheimer's [10][11] Upcoming Milestones - Data from the ABATE trial in phase two, partnered with Takeda, is expected in December [14] - Results on immunogenicity and pharmacodynamics for ACI-7104 are anticipated, with a focus on alpha-synuclein reduction in the brain [15][18] - The company plans to submit IND CTA for several small molecules by December, with clinical trials starting early next year [15] Market Position and Strategy - AC Immune positions itself as a leader in active immunotherapy, which is seen as a safer and more effective long-term treatment option compared to monoclonal antibodies [21] - The company aims to transition into phase three development based on encouraging data from ongoing trials [19][20] Collaboration and Future Directions - The small molecule Tau program is partnered with Eli Lilly, with decisions on clinical lead molecules expected soon [25] - The company is exploring both CNS and non-CNS applications for its NLRP3 inhibitors, with a focus on neuroinflammation and metabolic diseases [26][27] Additional Insights - The company is optimistic about the potential of its therapies to modify disease progression in Alzheimer’s and other neurodegenerative conditions [13][24] - There is a growing interest in the role of inflammation in neurodegenerative diseases, which AC Immune aims to address through its innovative therapies [26][27]

Core Insights - AC Immune SA will participate in the Jefferies Global Healthcare Conference in London from November 17-20, 2025, including a fireside chat and one-on-one investor meetings [1][2] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [3] - The company utilizes two clinically validated technology platforms, SupraAntigen® and Morphomer®, to develop a diversified pipeline of therapeutic and diagnostic programs, with candidates in Phase 2 and Phase 3 development [3] - AC Immune has established strategic partnerships with leading global pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [3]

Core Insights - AC Immune reported a quarterly loss of $0.2 per share, which was better than the Zacks Consensus Estimate of a loss of $0.22, representing an earnings surprise of +9.09% [1] - The company posted revenues of $1.17 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 22.51%, and a significant decline from $29.45 million in the same quarter last year [2] - The stock has gained approximately 17.8% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of AC Immune's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is -$0.22 on revenues of $1.96 million, and for the current fiscal year, it is -$0.91 on revenues of $6.05 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]

Financial Performance - Total revenue for Q3 2025 was CHF 939,000, a decrease of 96.3% compared to CHF 25,485,000 in Q3 2024[2] - Operating loss for Q3 2025 was CHF 16,166,000, compared to an operating income of CHF 7,269,000 in Q3 2024[2] - Net loss for the nine months ended September 30, 2025, was CHF 56,074,000, compared to a net loss of CHF 35,119,000 for the same period in 2024[3] - Total comprehensive loss for the nine months ended September 30, 2025, was CHF 53,325,000, compared to a loss of CHF 35,092,000 for the same period in 2024[3] - For the three months ended September 30, 2025, the basic loss per share was CHF (0.16), compared to a profit of CHF 0.06 in the same period of 2024[35] - For the nine months ended September 30, 2025, the net loss attributable to equity holders was CHF (56,074) thousand, compared to a loss of CHF (35,119) thousand in 2024[35] Assets and Equity - Total assets decreased to CHF 171,607,000 as of September 30, 2025, from CHF 230,913,000 as of December 31, 2024, representing a decline of 25.6%[1] - Shareholders' equity fell to CHF 62,444,000 as of September 30, 2025, down from CHF 112,270,000 at the end of 2024, a decrease of 44.5%[1] - Cash and cash equivalents decreased to CHF 27,741,000 as of September 30, 2025, from CHF 36,275,000 at the end of 2024, a decline of 23.5%[1] - As of September 30, 2025, the company had cash and short-term financial assets totaling CHF 108.4 million, consisting of CHF 27.7 million in cash and CHF 80.7 million in short-term financial assets[20] - Short-term financial assets due in one year or less decreased to CHF 80,727 thousand as of September 30, 2025, compared to CHF 129,214 thousand at the end of 2024[44] Revenue and Contracts - For the three months ended September 30, 2025, AC Immune generated CHF 0.9 million in contract revenues, a significant decrease from CHF 25.5 million in the same period of 2024, representing a decline of approximately 96.5%[23] - For the nine months ended September 30, 2025, total contract revenues were CHF 3.2 million, down from CHF 26.2 million in the prior year, indicating a decrease of about 87.8%[23] - The company recorded CHF 86.4 million in deferred contract revenue related to unsatisfied performance obligations as of September 30, 2025[34] - AC Immune received an upfront payment of USD 100 million (CHF 92.3 million) from Takeda Pharmaceuticals in May 2024 as part of a licensing agreement for active immunotherapies targeting Abeta[26] - The potential total value of the agreement with Takeda could reach approximately USD 2.1 billion (CHF 1.7 billion) if all related milestones are achieved[26] Expenses and Costs - Research and development expenses for the nine months ended September 30, 2025, were CHF 45,813,000, slightly down from CHF 46,785,000 in the same period of 2024[2] - The company incurred restructuring costs during Q3 2025, primarily related to employee termination benefits, as part of cost-reduction initiatives[16] - The company incurred CHF 0.4 million in net restructuring expenses for the period ended September 30, 2025, which included CHF 2.1 million in termination benefits[54] - The total cash outflow for leases for the nine months ended September 30, 2025, was CHF 1,448 thousand, compared to CHF 1,150 thousand in the prior year[40] - The expense charged against the income statement for share-based compensation was CHF 0.8 million for the three months ended September 30, 2025, compared to CHF 1.2 million in 2024[51] Financial Position and Liabilities - The total accrued expenses as of September 30, 2025, were CHF 11,993 thousand, slightly down from CHF 12,098 thousand at the end of 2024[41] - The carrying amount of property, plant, and equipment as of September 30, 2025, was CHF 2,208 thousand, down from CHF 2,651 thousand at the end of 2024[36] - The acquired IPR&D asset for the treatment of Parkinson's disease has a carrying amount of CHF 50,416 thousand as of September 30, 2025, unchanged from December 31, 2024[42] Financial Gains and Losses - The company reported a finance result, net of CHF 308,000 for Q3 2025, compared to a loss of CHF 1,766,000 in Q3 2024[2] - For the three months ended September 30, 2025, AC Immune recorded CHF 0.3 million in net financial gains, compared to CHF 1.8 million in net financial losses for the same period in 2024[52] - For the nine months ended September 30, 2025, AC Immune reported net financial losses of CHF 1.2 million, an improvement from CHF 1.4 million in losses for the same period in 2024[53] Corporate Strategy and Risks - The company has established a three-pillar corporate strategy targeting Alzheimer's disease, non-Alzheimer's neurodegenerative diseases, and diagnostics[9] - The company is exposed to various risks, including uncertainties regarding the success of current projects and the ability to raise additional capital as needed[21] Other Information - The company is currently evaluating the impact of the new IFRS 18 standard on its financial statement presentation and disclosures, which will be effective from January 1, 2027[19] - Management evaluated subsequent events and determined there were no other events warranting disclosure or recognition in the financial statements[58] - The company recognized a CHF 1.8 million gain on curtailment related to the defined benefit liability for the three and nine months ended September 30, 2025, compared to nil in the corresponding periods for 2024[57] - The aggregate decrease in net employee defined benefit liabilities was CHF 4.3 million, resulting from the curtailment and remeasurement of the plan[57] - Other comprehensive income of CHF 2.7 million was recognized during the period due to the remeasurement of the defined benefit plan[57]

Core Insights - AC Immune SA reported its financial results for Q3 2025, highlighting a strategic focus on high-value assets and advancements in its pipeline for neurodegenerative diseases [2][3][5] Financial Performance - The company had cash resources of CHF 108.5 million as of September 30, 2025, which is expected to fund operations until the end of Q3 2027, excluding potential milestone payments [6][10] - R&D expenses for Q3 2025 were CHF 13.1 million, a decrease from CHF 14.5 million in Q3 2024, primarily due to lower spending on the ACI-24.060 ABATE study [9][10] - The company reported a net loss of CHF 15.9 million for Q3 2025, compared to a net income of CHF 5.5 million in Q3 2024, largely due to the recognition of a CHF 24.6 million milestone in Q3 2024 [10][16] Pipeline and Development - The company is advancing three Phase 2 active immunotherapy programs and small molecule programs targeting NLRP3, Tau, and alpha-synuclein [3][6][7] - Upcoming milestones include interim results from the VacSYn trial of ACI-7104.056 for Parkinson's disease and the ABATE Phase 2 trial for ACI-24.060 in Alzheimer's disease, both expected in Q4 2025 [8][9] Research and Publications - AC Immune published significant research findings in peer-reviewed journals, including clinical data on ACI-35.030 in eBioMedicine and preclinical data on PET tracers for TDP-43 pathology in Nature Communications [6][7] Corporate Strategy - Following a strategic review, the company has reduced its workforce by approximately 30% to sharpen its investment focus on key assets [7][10] - The appointment of Prof. Catherine Mummery as Chair of the Clinical Advisory Board is aimed at enhancing the company's expertise in dementia clinical trials [7]

Core Insights - AC Immune SA has appointed Prof. Catherine Mummery as Chairwoman of its Clinical Advisory Board, bringing extensive experience in dementia clinical trials and neurodegenerative diseases [2][5][6] Company Overview - AC Immune is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [2][8] - The company utilizes two validated technology platforms, SupraAntigen® and Morphomer®, to develop a diverse pipeline of therapeutic and diagnostic programs [8][10] Leadership and Expertise - Prof. Mummery has led over 20 early-stage studies on disease-modifying agents in dementia and has been involved in significant clinical trials, including AC Immune's ACI-35.030 [4][5] - The Clinical Advisory Board (CAB) includes other notable experts in the field, enhancing the company's strategic clinical development and regulatory advice [6][8] Clinical Development Focus - The company is advancing its pipeline of active immunotherapies, with several candidates in Phase 2 development and novel therapeutics targeting intracellular mechanisms of neurodegenerative diseases [5][9] - Prof. Mummery expressed enthusiasm for leading the CAB as the company approaches critical milestones in clinical trials [5][9]

Core Insights - AC Immune SA has published preclinical data on its first-in-class TDP-43 PET tracer, ACI-19626, which shows potential for precision medicine in neurodegenerative diseases [2][4][6] Group 1: TDP-43 and Neurodegenerative Diseases - TDP-43 is a key component in the pathology of several neurodegenerative diseases, including ALS, FTD, LATE, and is also associated with Alzheimer's and Parkinson's diseases [3][6] - The shared clinical features of these diseases complicate differential diagnosis, highlighting the need for reliable biomarkers [3][6] Group 2: ACI-19626 PET Tracer Characteristics - ACI-19626 demonstrates high specificity and selectivity for pathological TDP-43 aggregates, with rapid brain uptake and fast washout, indicating its potential for effective imaging in living patients [4][7] - The tracer shows excellent selectivity for TDP-43 over common co-pathologies such as Abeta, Tau, and alpha-synuclein, with no off-target binding against a wide range of receptors and enzymes [7] Group 3: Clinical Development and Future Prospects - ACI-19626 has been advanced into a Phase 1 clinical study, with initial readout expected in Q4 2025, aiming to facilitate the detection of TDP-43 pathology in patients [6][8] - The CEO of AC Immune emphasized the potential of accurate PET imaging to improve diagnosis and enable earlier therapeutic interventions, which could significantly impact clinical trial design and patient stratification [5][6]

Core Insights - AC Immune SA has published preclinical data on its first-in-class TDP-43 PET tracer, ACI-19626, which shows potential for precision medicine in neurodegenerative diseases [2][5][6] - TDP-43 pathology is a significant factor in various neurodegenerative diseases, complicating diagnosis due to overlapping clinical features [3][6] - ACI-19626 demonstrates high specificity and selectivity for TDP-43 aggregates, with promising pharmacokinetic properties [4][7][8] Company Overview - AC Immune SA is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative diseases, including Alzheimer's and Parkinson's diseases [10] - The company utilizes two technology platforms, SupraAntigen® and Morphomer®, to develop a diversified pipeline of therapeutic and diagnostic programs [10] - AC Immune has established strategic partnerships with leading pharmaceutical companies, resulting in over $4.5 billion in potential milestone payments and royalties [10] Research and Development - The publication in Nature Communications details the characterization of ACI-19626, highlighting its potential to improve diagnosis and treatment of TDP-43 proteinopathies [5][6] - ACI-19626 has been advanced into Phase 1 clinical trials, with initial results expected in Q4 2025 [5][6][8] - The tracer shows excellent selectivity for TDP-43 over other common co-pathologies, indicating its potential as a diagnostic tool [7][8]